Alviss.ai CEO and Founder Dr. Pavel Overtchouk talks about how the company’s stroke prediction software seeks to be the first attempt to apply predictive medicine to cardiovascular interventions and heart surgery.
Five months after raising $55 million to back a new technology and a promising lead cancer immunotherapy, Asher Biotherapeutics has reeled in $108 million more. CEO Craig Gibbs said investors were enticed by encouraging new data suggesting Asher Bio’s lead program is superior to a competitor's.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
We're looking for entries for our MedCity ENGAGE Pitch Perfect contest from a wide variety of startups. Last year's winner was Care+Wear with apparel designed for people receiving treatment for cancer and other conditions.